Market cap
$17,181 Mln
Recently Viewed
Clear AllMarket cap
$17,181 Mln
Revenue (TTM)
$1,074 Mln
P/E Ratio
65.4
P/B Ratio
11.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$267 Mln
ROE
0.2 %
ROCE
9.6 %
Industry P/E
26.8
EV/EBITDA
57.9
Debt to Equity
--
Book Value
$--
EPS
$5.8
Face value
--
Shares outstanding
45,091,200
CFO
$1,604.70 Mln
EBITDA
$1,535.80 Mln
Net Profit
$1,162.54 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ABIOMED Inc (ABMD)
| 6.1 | 0.8 | 54.1 | 11.0 | 32.7 | 14.7 | 39.5 |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P 100#
| 3.5 | 15.9 | 4.2 | 32.9 | 23.2 | 13.4 | 14.6 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
ABIOMED Inc (ABMD)
| 6.1 | 10.8 | 90.0 | -47.5 | 72.9 | 66.3 | 24.8 |
|
S&P 100
| -22.1 | 27.6 | 19.3 | 29.5 | -5.8 | 19.3 | 8.8 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a... percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson. Read more
Chairman, CEO & Pres
Mr. Michael R. Minogue
Chairman, CEO & Pres
Mr. Michael R. Minogue
Headquarters
Danvers, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of ABIOMED Inc (ABMD) is $381.02 (NASDAQ) as of 23-Dec-2022 09:30 EDT. ABIOMED Inc (ABMD) has given a return of 32.74% in the last 3 years.
The P/E ratio of ABIOMED Inc (ABMD) is 65.36 times as on 20-Jan-2023, a 144 premium to its peers’ median range of 26.80 times.
The P/B ratio of ABIOMED Inc (ABMD) is 11.13 times as on 20-Jan-2023, a 529 premium to its peers’ median range of 1.77 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
111.62
|
10.14
|
|
2021
|
65.01
|
11.03
|
|
2020
|
32.89
|
6.27
|
|
2019
|
50.72
|
14.02
|
|
2018
|
119.33
|
19.41
|
The 52-week high and low of ABIOMED Inc (ABMD) are Rs -- and Rs -- as of 01-May-2026.
ABIOMED Inc (ABMD) has a market capitalisation of $ 17,181 Mln as on 20-Jan-2023. As per SEBI classification, it is a Large Cap company.
Before investing in ABIOMED Inc (ABMD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.